Efficacy and safety of intravenous secukinumab for the treatment of active psoriatic arthritis: Results from the randomized, placebo-controlled Phase III INVIGORATE-2 study
Arthritis Rheumatol 2024 doi: 10.1002/art.42997
IV secukinumab provided rapid and sustained improvements in disease signs and symptoms at Week 16 and through 52 weeks. Kivitz et al. evaluated the long-term efficacy, safety, and tolerability of IV secukinumab in patients with active PsA.
A significantly higher proportion of patients receiving IV secukinumab achieved ACR50 at Week 16 compared with placebo. All Week 16 secondary efficacy endpoints were met. Placebo patients who switched to IV secukinumab achieved comparable response rates by Week 52. The safety profile of IV secukinumab was consistent with that previously reported for SC secukinumab and no new safety signals were observed.
Keywords:
